Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News vTv Therapeutics Inc VTVT

Healthcare Biotechnology
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of... see more

Recent & Breaking News (NDAQ:VTVT)

vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2021

vTv Therapeutics Announces Deepa Prasad as New President and CEO

PR Newswire October 20, 2021

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

GlobeNewswire October 12, 2021

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

GlobeNewswire September 23, 2021

vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire August 4, 2021

vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737

GlobeNewswire June 29, 2021

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

GlobeNewswire June 22, 2021

vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

GlobeNewswire May 5, 2021

vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes

GlobeNewswire April 13, 2021

TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin

GlobeNewswire April 12, 2021

vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399

GlobeNewswire March 23, 2021

vTv Therapeutics Announces Initiation of Study Evaluating TTP399's Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

GlobeNewswire March 18, 2021

vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 8, 2021

vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

GlobeNewswire February 24, 2021

vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes

GlobeNewswire February 23, 2021

vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

GlobeNewswire February 17, 2021

vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually

GlobeNewswire January 6, 2021

vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

GlobeNewswire December 15, 2020

Aditum Bio Announces Formation of Third Company, Anteris Bio

PR Newswire December 15, 2020

vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio

GlobeNewswire December 15, 2020